2011 Scrip Asia 100 - Aslan Pharma doing the lion's work in Asian drug development
This article was originally published in Scrip
Executive Summary
Deprioritised assets from mid-sized and large pharmaceutical companies in North America and Europe have become a promising source of compounds for Aslan Pharmaceuticals, a Singaporean firm with a unique business model, its CEO, Dr Carl Firth, tells Ian Haydock. This article is part of the 2011 Scrip Asia 100.